One of our listeners who reached out on Reddit, in fact, asked Auricchio about the biggest obstacles preventing gene therapy from treating more diseases.

There are several bottlenecks.

Some of them are actually scientific bottlenecks and some of them are more economic bottlenecks.

So the delivery bottlenecks are related, for instance, to vectors.

And I'll give you an example of this.

When vectors are derived from viruses, they can have some limitations.

In particular, one class of these viruses that is the predominant virus used for in vivo gene therapy, which is the aden-associated virus, is that it is a small virus.

This characteristic serves as the premise for a specific debate, which we'll investigate thanks to the question of a very well-prepared listener who asked In Europe, when will regulators allow the reuse of clinical data from gene editors across different mutations within the same gene?